PKN1-ANXA4 (Aex2Pex13)

ANXA4-PKN1 · Variant type: fusion · Fusion partner: ANXA4 (Aex2Pex13)

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Repotrectinib	92.7%	7.3%	84.21
2	Darovasertib	88.7%	11.3%	96.99
3	Upadacitinib	74.5%	25.5%	97.98
4	Fedratinib	73.6%	26.4%	96.21
5	Capivasertib	71.7%	28.3%	96.48
6	Pacritinib	66.6%	33.4%	88.64
7	Gilteritinib	56.6%	43.4%	88.97
8	Defactinib	56.1%	43.9%	92.68
9	Abemaciclib	54.2%	45.8%	91.48
10	Sunitinib	44.3%	55.7%	91.73
11	Rabusertib	42.0%	58.0%	98.74
12	Entrectinib	36.1%	63.9%	93.69
13	Abrocitinib	19.6%	80.4%	99.50
14	Pralsetinib	15.7%	84.3%	93.43
15	Mitapivat	13.3%	86.7%	100.00
16	Avapritinib	12.6%	87.4%	97.73
17	Neratinib	10.1%	89.9%	93.18
18	Palbociclib	7.7%	92.3%	98.75
19	Ripretinib	7.5%	92.5%	92.95
20	Selpercatinib	7.4%	92.6%	96.72
21	Mobocertinib	6.9%	93.1%	97.22
22	Zanubrutinib	6.3%	93.7%	98.24
23	Tenalisib	6.1%	93.9%	97.98
24	Futibatinib	5.9%	94.1%	98.48
25	Canertinib	5.5%	94.5%	96.49

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Repotrectinib	92.7%	—	—
Darovasertib	88.7%	—	—
Upadacitinib	74.5%	—	—
Fedratinib	73.6%	—	—
Capivasertib	71.7%	—	—
Pacritinib	66.6%	—	—
Gilteritinib	56.6%	—	—
Defactinib	56.1%	—	—
Abemaciclib	54.2%	—	—
Sunitinib	44.3%	—	—
Rabusertib	42.0%	—	—
Entrectinib	36.1%	—	—
Abrocitinib	19.6%	—	—
Pralsetinib	15.7%	—	—
Mitapivat	13.3%	—	—
Avapritinib	12.6%	—	—
Neratinib	10.1%	—	—
Palbociclib	7.7%	—	—
Ripretinib	7.5%	—	—
Selpercatinib	7.4%	—	—
Mobocertinib	6.9%	—	—
Zanubrutinib	6.3%	—	—
Tenalisib	6.1%	—	—
Futibatinib	5.9%	—	—
Canertinib	5.5%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 30.8ms